@article {169902,
	title = {HCV in Egypt, prevention, treatment and key barriers to elimination.},
	journal = {Expert review of anti-infective therapy},
	volume = {16},
	year = {2018},
	note = {n/a},
	month = {2018 04},
	pages = {345-350},
	abstract = {<p>INTRODUCTION: Currently, direct-acting antivirals (DAAs) are considered the ideal choice for the treatment of chronic HCV patients due to their proven efficacy (SVR\&gt; 90\%), and minimal adverse effects. Egypt launched a large treatment program aimed at providing treatment coverage for Egyptian HCV- infected patients. Areas covered: This review covers the treatment and prevention efforts made by the Egyptian National Committee for the Control of Viral Hepatitis (NCCVH) with the available model of care for HCV patients in Egypt, in addition to the barriers that prevent elimination of HCV from Egypt. Expert commentary: Egypt could provide a model for establishing the largest HCV management system aimed at eliminating HCV from the country with the highest worldwide prevalence. Despite the huge efforts and achieved results in combating the HCV epidemic in Egypt, certain improvements are needed in order to attain HCV elimination, such as the development of an enhanced screening program working in parallel to the present treatment options.</p>
},
	keywords = {Antiviral Agents, Egypt, Hepatitis C, Chronic, Humans, Mass Screening, Prevalence},
	issn = {1744-8336},
	doi = {10.1080/14787210.2018.1448709},
	author = {El Kassas, Mohamed and Tamer Elbaz and Elsharkawy, Aisha and Heba Omar and Gamal Esmat}
}
